Topics

FDA approves first therapy to treat patients with rare blood disorder

07:28 EST 8 Nov 2019 | FDA

FDA grants approval to Reblozyl (luspatercept–aamt) for the treatment of anemia in adult patients with beta thalassemia who require regular red-blood cell transfusions.

Original Article: FDA approves first therapy to treat patients with rare blood disorder

NEXT ARTICLE

More From BioPortfolio on "FDA approves first therapy to treat patients with rare blood disorder"

Quick Search